Lilly Boosts Sales View to $85 Billion on Obesity-Drug Surge

Eli Lilly & Co. surprised Wall Street by raising its annual sales and profit forecast, as demand for obesity medications soared and thousands of patients started taking its new weight-loss pill before advertising for the drug had even begun.

The drugmaker now sees 2026 sales rising to as much as $85 billion, up from its earlier guidance of up to $83 billion, it said in a statement Thursday. The company forecast 2026 profits in the range of $35.50 a share to $37 a share, higher than its earlier guidance of $33.50 a share to $35 a share.